Vulvar squamous cell carcinoma
MONDO:0024609An invasive squamous cell carcinoma arising from the vulva. Risk factors include the human papilloma virus and cigarette smoking. Precursor lesions include the vulvar intraepithelial neoplasia, lichen sclerosus with associated squamous cell hyperplasia, and chronic granulomatous vulvar disease such as granuloma inguinale. Symptoms include vulvar pruritus or irritation, discharge, bleeding, and pain. The following morphologic variants have been identified: keratinizing, non-keratinizing, basaloid, warty, verrucous, keratoacanthoma-like, and squamous cell carcinoma with tumor giant cells. Risk factors for recurrence include advanced stage, tumor diameter greater than 2.5 cm, multifocality, capillary-like space involvement, associated vulvar intraepithelial neoplasia grades 2 or 3, and margins of resection involved by tumor. (WHO, 2003)
Also known as: epidermoid carcinoma of the vulva, epidermoid carcinoma of vulva, epidermoid cell carcinoma of the vulva, epidermoid cell carcinoma of vulva, mammalian vulva squamous cell carcinoma, squamous cell carcinoma of the vulva, squamous cell carcinoma of vulva, vulva epidermoid carcinoma
2859 clinical trials for this condition and its sub-types, 22 tagged with Vulvar squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Vulvar squamous cell carcinoma
-
1 sub-type
-
Vulva verrucous carcinoma 0 trials
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo therapy shows promise for Hard-to-Treat vulvar cancer
Disease control OngoingThis study tests whether combining standard chemotherapy (cisplatin) and radiation with an immunotherapy drug (pembrolizumab) can shrink or control advanced vulvar cancer that cannot be removed by surgery. The trial includes 24 adults with unresectable, recurrent, or metastatic v…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental combo targets Hard-to-Treat HPV cancers
Disease control OngoingThis study tests a combination of two drugs—TG4001 (a biologic that targets HPV) and avelumab (an immunotherapy)—in people with advanced HPV-16 cancers that cannot be removed by surgery or cured by radiation. The trial has two phases: first, to find a safe dose, and second, to se…
Phase 1/2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Custom immune cells take on multiple cancers in early trial
Disease control OngoingThis early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…
Phase 1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Keytruda takes on 15 advanced cancers in major trial
Disease control OngoingThis phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New dye could replace radioactive tracers in vulvar cancer surgery
Diagnosis OngoingThis study tests whether a dye called indocyanine green (ICG) used with near-infrared imaging can find sentinel lymph nodes as well as the standard radioactive tracer method in people with early-stage vulvar cancer. About 22 participants will receive both methods during surgery t…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
Blood test may help cancer patients avoid nerve damage from chemo
Knowledge-focused PausedThis pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC